Clinical data | |
---|---|
Other names | BTRX-140; CYM-53093; NMRA-140; NMRA-335140 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C25H32FN5O2 |
Molar mass | 453.562 g·mol−1 |
3D model (JSmol) | |
| |
|
Navacaprant (developmental code names include BTRX-335140, BTRX-140, CYM-53093, NMRA-335140, and NMRA-140), is a selective κ-opioid receptor antagonist which is under development for the treatment of major depressive disorder.[1][2][3] As of December 2023, navacaprant is in phase 3 clinical trials for this indication.[4]